Recordati acquires rights to Enjaymo

Italian pharma major Recordati (RECI: MI)saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines.

Recordati has signed a deal with French major Sanofi (Euronext: SAN) to acquire the global rights to Enjaymo (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.

Enjaymo (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults with CAD.